The information presented in this article is for educational and research purposes only, intended for laboratory professionals, researchers and collaborators. This content does not constitute medical or clinical advice.

The Stamakort peptide is one of the more closely studied members of the bioregulator class, and much of its appeal in the laboratory comes down to size. Short peptides can be small enough to cross the cell membrane and the nuclear envelope, where they interact directly with DNA (Khavinson et al., 2021).

Within the Khavinson bioregulator system, Stamakort carries the A-10 designation and is associated with gastric tissue. It belongs to a family of organ-derived peptide complexes studied for tissue-directed activity rather than broad, system-wide effects.

This guide reviews what the Stamakort peptide is, how short peptide bioregulators are thought to work, and where the compound fits into in vitro research. All information here is for research use only. Stamakort is not a therapeutic product.

What Is the Stamakort Peptide Bioregulator?

Stamakort is a peptide complex associated with gastric mucosa and labeled A-10 in the bioregulator naming system. It is supplied in capsule format and grouped with the family of low-molecular peptide preparations developed from animal tissue extracts.

The bioregulator concept rests on a simple premise. Each tissue appears to rely on its own set of short regulatory peptides, and a preparation drawn from a given organ is studied for activity on that same organ (Khavinson, 2002).

For a broader primer on this compound class, see our overview of what peptide bioregulators are.

Origins in Khavinson Bioregulator Research

The bioregulator family traces back to research led by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. Their work produced peptide preparations from tissues including the pineal gland, thymus, prostate, and retina (Khavinson, 2002).

From the amino acid profiles of these preparations, the group went on to design short synthetic peptides with tissue-directed activity. Stamakort sits in the gastric branch of this larger program.

How Short Peptide Bioregulators Work

The research interest in short peptides centers on a mechanism that sets them apart from larger proteins. Because of their small size, they can reach the cell nucleus and act at the level of the gene rather than only at the cell surface.

DNA and Gene Expression Regulation

A systematic review of peptide regulation reports that short peptides of two to seven amino acids can penetrate into nuclei, interact with histone proteins, and bind both single- and double-stranded DNA (Khavinson et al., 2021). Through these interactions, peptides are described as modulating DNA methylation and the activation or repression of specific genes.

Molecular docking studies add detail to this picture. Modeling of short peptides against DNA found that several bind defined nucleotide sequences within gene promoter regions, with different peptides recognizing different sites (Khavinson et al., 2016).

Tissue-Specific Activity

The tissue-directed behavior of these peptides has been examined in organotypic culture. In one set of experiments, synthetic peptides stimulated the outgrowth of explants from the tissue matching the peptide’s origin, while leaving unrelated tissues unaffected (Khavinson, 2001).

This selectivity is the main reason the bioregulator family is organized by organ. A gastric-associated peptide such as Stamakort is studied in gastric models rather than as a general-purpose agent. For more on how this class differs from conventional peptides, see bioregulators vs peptides.

The Peptide Theory of Aging and Gastric Tissue

Stamakort is often discussed alongside a broader idea known as the peptide theory of aging. Under this framework, aging is described as a process of changing gene expression that lowers the synthesis of regulatory and tissue-specific peptides, which in turn affects the structure and function of organs (Khavinson, 2002).

The proposed research response is to study whether supplying tissue-matched peptides can support the normal regulatory signals of that tissue in a model system.

Why Organ-Specific Peptides Are Studied Separately

Because each tissue appears to use its own peptide signals, researchers treat organ-derived preparations as distinct compounds rather than interchangeable ones. A retinal peptide, a thymic peptide, and a gastric peptide each carry their own research profile.

This is why a stomach-associated compound is catalogued on its own. Adjacent digestive-organ bioregulators such as Pancragen (pancreas) and Livagen (liver) are studied as separate entries in the same family.

In Vitro Research on Bioregulator Peptides

Much of the laboratory work on this peptide class uses cell culture systems. These models let researchers observe peptide activity on proliferation, differentiation, and gene expression under controlled conditions.

Cell Differentiation and Aging Culture Models

Short peptides have been studied as regulators of cell differentiation, with reports that specific sequences direct pluripotent cells toward particular lineages depending on peptide structure and concentration (Khavinson et al., 2020a).

In aging cell cultures, short peptides at nanomolar concentrations modulated the expression of genes tied to cellular aging, including genes linked to growth signaling and telomere maintenance (Ashapkin et al., 2020). Findings like these shape how researchers design in vitro protocols for the bioregulator family.

Inflammatory and Proliferative Pathways

A 2022 study tested several Khavinson peptides on a monocyte and macrophage cell line. The peptides modulated proliferative signaling, and one of them, the bronchial-derived Chonluten tripeptide, lowered the release of inflammatory markers in cells exposed to bacterial lipopolysaccharide (Avolio et al., 2022).

Work of this kind models how organ-derived peptides behave at the cellular level. For a closer look at one peptide from that study, see our article on Chonluten.

Stamakort Within the Bioregulator Family

Stamakort is one entry in a wider catalog of organ-specific bioregulators, each tied to a different tissue. Grouping them this way reflects the tissue-specific activity reported across the class (Khavinson, 2001).

Researchers comparing compounds within the family often start with the shared mechanism, then narrow to the organ of interest. The table below summarizes potential in vitro research applications studied for short peptide bioregulators.

Quality and Sourcing Considerations for Researchers

BioLongevity Labs supplies research compounds with third-party analytical documentation. You can review our approach to third-party testing and our USA-based manufacturing standards.

For laboratory work, compound documentation matters as much as the compound itself. Reproducible results depend on knowing the identity, purity, and consistency of each batch.

Conclusion

The Stamakort peptide is best understood as a research compound rather than a finished product. Its place in the literature comes from the bioregulator model, where short, tissue-directed peptides interact with DNA to modulate gene expression.

For laboratories studying gastric tissue models or the bioregulator class as a whole, Stamakort offers a defined, organ-associated compound with a documented research lineage. All Stamakort research applications are for in vitro and laboratory use only. The compound is not intended for consumption.

References

[1] Khavinson, V. Kh. (2002). Peptides and ageing. Neuro Endocrinology Letters, 23(Suppl 3), 11-144. https://pubmed.ncbi.nlm.nih.gov/12374906/

[2] Khavinson, V. K. (2001). Tissue-specific effects of peptides. Bulletin of Experimental Biology and Medicine, 132(2), 807-808. doi:10.1023/a:1013058701974

[3] Khavinson, V. K., Popovich, I. G., Linkova, N. S., Mironova, E. S., & Ilina, A. R. (2021). Peptide regulation of gene expression: A systematic review. Molecules, 26(22), 7053. doi:10.3390/molecules26227053

[4] Khavinson, V. K., Lin’kova, N. S., & Tarnovskaya, S. I. (2016). Short peptides regulate gene expression. Bulletin of Experimental Biology and Medicine, 162(2), 288-292. doi:10.1007/s10517-016-3596-7

[5] Khavinson, V., Linkova, N., Diatlova, A., & Trofimova, S. (2020). Peptide regulation of cell differentiation. Stem Cell Reviews and Reports, 16(1), 118-125. doi:10.1007/s12015-019-09938-8

[6] Avolio, F., Martinotti, S., Khavinson, V. K., Esposito, J. E., Giambuzzi, G., Marino, A., … Toniato, E. (2022). Peptides regulating proliferative activity and inflammatory pathways in the monocyte/macrophage THP-1 cell line. International Journal of Molecular Sciences, 23(7), 3607. doi:10.3390/ijms23073607

[7] Ashapkin, V., Khavinson, V., Shilovsky, G., Linkova, N., & Vanyushin, B. (2020). Gene expression in human mesenchymal stem cell aging cultures: Modulation by short peptides. Molecular Biology Reports, 47(6), 4323-4329. doi:10.1007/s11033-020-05506-3

The information presented in this article is for educational and research purposes only, intended for laboratory professionals, researchers and collaborators. This content does not constitute medical or clinical advice.

Pielotax is a kidney peptide bioregulator built around a short-peptide complex isolated from kidney tissue. It belongs to a family of organ-specific peptide preparations developed within Russian gerontology research and is studied today only for laboratory and in vitro work.

This article covers what Pielotax is, where it sits in the peptide bioregulator class, and what published research shows about the short peptides behind it. All information here is for research use only.

What Is Pielotax?

Pielotax is a peptide bioregulator associated with kidney tissue. In research catalogs it is listed as Peptide Complex A-9.

It is made up of short peptides, chains of only a few amino acids, originally isolated from the kidney tissue of young animals. Preparations in this class carry a low-molecular-weight peptide fraction, with peptides small enough to enter cells and reach the nucleus.

Pielotax sits alongside other organ-specific bioregulators that each map to a single tissue. To place it in context, it helps to start with the wider class. You can read more in our overview of peptide bioregulators and how bioregulators differ from other peptides.

Where Pielotax Fits in the Bioregulator Class

Pielotax is one entry in a much larger catalog of tissue-matched peptide preparations. Its place in that catalog explains a lot about how researchers study it.

The Khavinson Peptide Lineage

The bioregulator concept traces to Professor Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology. Work there began with peptide fractions extracted from animal organs and later moved to defined synthetic short peptides.

The guiding idea is that each organ produces its own short peptides that help regulate the activity of that organ’s cells. A kidney-derived preparation such as Pielotax is studied for kidney tissue, a pineal-derived one for pineal tissue, and so on across the catalog.

Organ-Specific Peptide Complexes

Pielotax belongs to the A-series of peptide complexes, each labeled for its source tissue.

Researchers often study these compounds side by side. Related entries in the catalog include the Cerluten nervous-system bioregulator, and within the urinary and urogenital area, the Chitomur bladder peptide and the Prostamax prostate peptide.

How Peptide Bioregulators Are Thought to Work

The reason a kidney peptide is studied on kidney tissue comes down to a proposed mode of action at the level of the gene. Two research threads describe it.

Peptide-DNA Complementary Binding

One model holds that short regulatory peptides bind directly to DNA. According to PubMed, a 2005 analysis proposed that the DNA double helix recognizes and binds regulatory peptides in a way similar to transcription factors, with the peptide settling into the major groove of the helix.

Later work used molecular docking to map specific peptides to short, complementary nucleotide sequences in target gene promoters, a step tied to gene activation.

In this model, a peptide acts as a small signal that can switch particular genes on or off.

Tissue-Specific Gene Regulation

The second thread is tissue specificity. Research on cultured cells reports that different short peptides raise cell-differentiation factors only in the matching tissue.

According to PubMed, one study found that pancreatic, bronchial, and prostate-derived peptides each raised differentiation markers in their own cell type, and the effect was stronger in aged cultures.

This tissue-matched pattern is the research rationale for studying a kidney peptide like Pielotax in kidney-tissue models rather than as a general agent.

What Research Shows About Short Peptides and Cellular Aging

Direct, indexed studies on the Pielotax kidney complex are limited. Most peer-reviewed work covers related short peptides from the same class, so the findings below describe the class, not Pielotax itself.

Several in vitro studies look at how these peptides behave in aging cell cultures:

• In aging skin-fibroblast cultures, the KE and AED peptides changed expression of sirtuins and collagen I, markers tied to cell maintenance.
• In long-term stem-cell cultures, the AEDG and KED peptides lowered the senescence markers p16 and p21.
• The pineal tetrapeptide Epitalon (AEDG) increased telomere length in cultured cell lines by raising telomerase activity, and a 2025 study reported telomerase activation in cultured bovine oocytes and early embryos.

A 2025 review of Epitalon collects much of this in vitro and in silico data in one place. Earlier work also connects short peptides to the telomere-length regulator irisin.

Together these studies describe a class that acts on gene expression and cell-aging markers in culture.

Pielotax and Kidney Tissue Research Context

Applying that class-level picture to the kidney is where the open questions sit.

The tissue-specificity model predicts that a kidney-sourced peptide complex would act on kidney-tissue cells. Indexed, peer-reviewed studies on the specific Pielotax complex remain sparse, and much of the original renal work appeared decades ago in Russian-language journals that are not well indexed today.

That gap makes Pielotax a candidate for fresh in vitro study rather than a settled question. Renal cell cultures and aged-cell models are the natural settings for that work.

For researchers tracking kidney-related targets, the Klotho protein, produced largely in the kidney and studied in renal aging, offers a related line of inquiry.

Research-Grade Standards for Pielotax

Reliable research starts with reliable material, which is where sourcing and testing matter.

The quality of a peptide preparation shapes the quality of the data it produces. BioLongevity Labs supplies research compounds with batch-level documentation, including third-party testing and USA-based GMP manufacturing.

Each batch ships with a Certificate of Analysis, so researchers can confirm identity and purity before any work begins.

Research Applications

The points above translate into a short set of in vitro and ex vivo directions where a kidney peptide complex can be studied.

Quick Review

Pielotax is a kidney peptide bioregulator, known in research as Peptide Complex A-9, drawn from the Khavinson family of organ-specific short peptides.

The published evidence centers on the short-peptide class as a whole, which research links to gene-level regulation and cell-aging markers in culture. How that picture maps onto kidney tissue is an open in vitro question.

Researchers can explore the wider peptide bioregulator catalog to compare organ-specific compounds. Pielotax and all related compounds are supplied for research use only.

References

[1] Khavinson V, Shataeva L, Chernova A. DNA double-helix binds regulatory peptides similarly to transcription factors. Neuro Endocrinol Lett. 2005;26(3):237-241. PubMed

[2] Khavinson VKh, Lin’kova NS, Tarnovskaya SI, et al. Short peptides stimulate serotonin expression in cells of brain cortex. Bull Exp Biol Med. 2014;157(1):77-80. doi:10.1007/s10517-014-2496-y

[3] Khavinson VKh, Linkova NS, Polyakova VO, et al. Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med. 2012;153(1):148-151. doi:10.1007/s10517-012-1664-1

[4] Fridman NV, Linkova NS, Kozhevnikova EO, et al. Comparison of the effects of KE and AED peptides on functional activity of human skin fibroblasts during their replicative aging. Bull Exp Biol Med. 2020;170(1):154-157. doi:10.1007/s10517-020-05022-1

[5] Sinjari B, Diomede F, Khavinson V, et al. Short peptides protect oral stem cells from ageing. Stem Cell Rev Rep. 2020;16(1):159-166. doi:10.1007/s12015-019-09921-3

[6] Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. doi:10.1007/s10522-025-10315-x

[7] Ullah S, Haider Z, Perera CD, et al. Epitalon-activated telomerase enhance bovine oocyte maturation rate and post-thawed embryo development. Life Sci. 2025;362:123381. doi:10.1016/j.lfs.2025.123381

[8] Araj SK, Brzezik J, Madra-Gackowska K, Szeleszczuk L. Overview of Epitalon: highly bioactive pineal tetrapeptide with promising properties. Int J Mol Sci. 2025;26(6):2691. doi:10.3390/ijms26062691

[9] Khavinson VKh, Kuznik BI, Tarnovskaya SI, Lin’kova NS. Short peptides and telomere length regulator hormone irisin. Bull Exp Biol Med. 2016;160(3):347-349. doi:10.1007/s10517-016-3167-y

The information presented in this article is for educational and research purposes only, intended for laboratory professionals, researchers and collaborators. This content does not constitute medical or clinical advice.

Visoluten is a polypeptide complex isolated from bovine retinal tissue, catalogued as the A-11 bioregulator in the Khavinson peptide classification system. It belongs to a class of tissue-specific short-chain peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology and has been a subject of laboratory investigation for several decades a 2002 foundational review of the peptide bioregulator research program.

This article is intended for researchers working in ocular biology, cellular aging, and peptide bioregulation. All compounds discussed are for research use only.

What Is Visoluten?

Visoluten is the common trade name for the A-11 retinal peptide complex — a preparation of short-chain amino acid sequences derived from the retinal tissue of young bovines. The compound carries a molecular weight of up to 10 kDa and consists of multiple peptide fractions rather than a single defined sequence as described in the comprehensive review of peptide bioregulators and aging.

It occupies a specific slot within the Khavinson cytomax classification: each cytomax targets a defined organ system, and the retinal peptides were among the earliest developed under this research program. The original patent dates to 1993 (RU Patent No. 1436305), with a second patent following in 1997 (RU Patent No. 2073518).

Visoluten differs from synthetic retinal peptides such as Epitalon, which is the defined tetrapeptide Ala-Glu-Asp-Gly. While Epitalon has also been studied in retinal degeneration models, Visoluten is a multi-fraction natural complex — making it a distinct research compound with a different mechanistic profile.

How Visoluten Fits Into the Khavinson Bioregulator Research Program

The Khavinson program is one of the more extensively documented tissue-specific peptide research initiatives in the biogerontology literature, spanning roughly four decades of output from the St. Petersburg Institute of Bioregulation and Gerontology.

The foundational thesis holds that aging corresponds to a progressive decline in the synthesis of regulatory and tissue-specific peptides. When that synthesis is disrupted, organ function degrades in ways that compound over time. The hypothesis, sometimes called the peptide theory of aging, proposes that delivering exogenous peptide complexes may help restore normal gene expression patterns within their target tissues as outlined in research from the St. Petersburg Institute of Bioregulation and Gerontology.

Each organ-targeted complex in the program — including those studied for the brain (Cerluten), vascular tissue (Vesugen), and retina (Visoluten) — is understood to act by binding chromatin and influencing transcriptional activity in tissue-specific ways. For a broader overview of how these compounds are classified and studied, see BioLongevity Labs’ guide to what peptide bioregulators are.

Visoluten’s retinal specificity is a central research question. Unlike generalist antioxidant formulations, the polypeptide fractions in Visoluten are proposed to act selectively within retinal cells rather than systemically — a claim that the laboratory literature has tested in several distinct model systems.

How Researchers Study Visoluten’s Mechanism

The primary mechanistic hypothesis is that Visoluten peptide fractions, once introduced to retinal cell cultures, interact with chromatin to upregulate tissue-specific protein synthesis. The effect is posited to bypass ordinary transcription bottlenecks associated with cellular aging as described in the Khavinson peptide aging review.

The supporting evidence for this mechanism comes from two directions: organotypic culture studies and animal degeneration models.

In organotypic culture studies, retinal polypeptide complexes have been tested against cultures of retinal tissue from both young and aged animals. Research from the St. Petersburg Institute using such models found that polypeptide complexes — including the retinal preparation — increased the expression of the proliferation marker Ki-67 and reduced expression of apoptotic markers p53 and caspase-3 as reported in a 2017 study in the Bulletin of Experimental Biology and Medicine. The effect was observed across multiple organ-type cultures, with a correlation noted between regenerative intensity and the age of the source animal.

Animal degeneration models, particularly Campbell rats with hereditary retinitis pigmentosa, have been used to study retinal bioregulator effects in vivo. Studies using the related tetrapeptide Epitalon — which shares the Ala-Glu-Asp-Gly sequence proposed to be relevant to both the pineal gland and retina — found that early and sustained administration preserved the morphological structure of the retina and maintained its bioelectrical activity over a longer period compared to untreated controls as published in the Bulletin of Experimental Biology and Medicine, 2002.

What the Research Literature Examines

The published record on retinal peptide bioregulators spans approximately three decades of output, with most of the foundational studies originating from the St. Petersburg Institute research group. Here is a structured look at the key research areas.

Retinal Cell Culture Models

Organotypic culture systems have been the primary in vitro tool for studying the retinal polypeptide complex. In these models, tissue-specific peptide preparations are introduced to retinal explant cultures, and changes in cellular markers are tracked over time.

A 2017 study published in the Bulletin of Experimental Biology and Medicine examined polypeptide complexes derived from multiple tissues — including retina, blood vessels, bronchi, and kidneys — in organotypic cultures from young and old animals Ryzhak et al., 2017. The retinal complex produced measurable changes in Ki-67 expression (upregulated) and p53 and caspase-3 expression (downregulated), consistent with a shift toward cell renewal and away from apoptotic signaling. The correlation between effect intensity and donor animal age was a notable secondary finding.

Retinitis Pigmentosa Animal Models

Campbell rats, which carry a hereditary form of retinal degeneration analogous to retinitis pigmentosa, have served as a widely used in vivo model for retinal bioregulator research.

In animal research, the tetrapeptide Epitalon — whose sequence the Khavinson program also associates with retinal transcriptional pathways — was studied for its effect on retinal morphology and electrical activity in this model. Administration beginning at birth preserved the morphological structure of the retina and increased its bioelectrical activity relative to control groups Khavinson et al., 2002, Bulletin of Experimental Biology and Medicine. A subsequent study found that maternal administration of the peptide before and during pregnancy extended this protective window — with retinal functional integrity preserved approximately twice as long compared to postnatal-only administration Khavinson et al., 2003, Bulletin of Experimental Biology and Medicine.

Clinical Observational Studies in Retinal Disease Contexts

The St. Petersburg research group also published clinical data on peptide bioregulator use in retinal disease contexts. A study examining 104 patients with diabetic retinopathy who received bioregulatory therapy — including the retinal preparation retinalamine alongside other organ-targeted peptide complexes — reported that 90% of cases showed improvement in visual acuity and ophthalmoscopic findings Trofimova and Khavinson, 2001, Vestn Oftalmol. Improvements included resolution of hemorrhages, reduction in macular edema, and normalization of retinal blood flow. No adverse changes in clinical picture were recorded across any of the cases.

A separate controlled clinical study using Epitalon in patients with pigmented retinal degeneration found a positive clinical effect in 90% of cases, with electroretinography confirming improved bioelectric and functional activity of the retina Khavinson et al., 2002, Neuro Endocrinol Lett. The authors proposed that the tetrapeptide participates in transcriptional mechanisms shared between the epiphysis and retina — pointing to the embryological connection between these two structures.

Visoluten in the Context of Other Ocular Research Peptides

Visoluten is not the only compound researchers investigate in ocular biology contexts. BioLongevity Labs’ article on peptides for ocular and retinal research covers the broader landscape of peptides studied in visual system contexts, including structural and vascular-support compounds.

Within the bioregulator category specifically, the retinal complex is typically studied alongside the vascular bioregulator (Ventfort/A-3) and the cerebral bioregulator (Cerluten/A-5), given that retinal health involves microvascular integrity as well as neural signaling. Researchers interested in the neural peptide side of this picture may also consult BioLongevity Labs’ coverage of Cortagen, the cortical peptide bioregulator, which sits in the same research program.

The common thread across these compounds is tissue specificity. Where antioxidant or anti-inflammatory compounds act broadly, Khavinson-program bioregulators are studied for selective action in their respective target tissues — a mechanistic distinction that continues to drive laboratory interest in this compound class.

Visoluten In Vitro Research Applications

Where to Source Visoluten for Research

For laboratories sourcing the A-11 retinal peptide complex, documentation standards matter significantly for experimental reproducibility.

BioLongevity Labs supplies BioRetina (Visoluten A-11) with triple third-party COA documentation covering HPLC purity verification, LC-MS molecular identity confirmation, and sterility and endotoxin testing. All batches are manufactured in a U.S. GMP-certified facility and ship with a full analytical dossier. Researchers can review COA results before purchase. For guidance on reading peptide COAs, BioLongevity Labs’ COA quality guide is a practical reference.

All BioLongevity Labs compounds, including Visoluten, are supplied strictly for research use.

References

[1] Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. https://pubmed.ncbi.nlm.nih.gov/12374906/

[2] Ryzhak AP, Chalisova NI, Lin’kova NS, Nichik TE, Dudkov AV, Kolchina NV, Ryzhak GA, Khalimov RI. Effect of Polypeptides on Cell Proliferation and Apoptosis during Aging. Bull Exp Biol Med. 2017;162(4):534-538. doi:10.1007/s10517-017-3655-8

[3] Khavinson V, Razumovsky M, Trofimova S, Grigorian R, Razumovskaya A. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett. 2002;23(4):365-8. https://pubmed.ncbi.nlm.nih.gov/12195242/

[4] Khavinson VKh, Razumovsky MI, Trofimova SV, Razumovskaya AM. Retinoprotective effect of Epithalon in Campbell rats of various ages. Bull Exp Biol Med. 2003;135(5):495-8. doi:10.1023/A:1024931812822

[5] Khavinson VKh, Razumovskii MI, Trofimova SV, Grigor’yan RA, Chaban TV, Oleinik TL, Razumovskaya AM. Effect of epithalon on age-specific changes in the retina in rats with hereditary pigmentary dystrophy. Bull Exp Biol Med. 2002;133(1):87-9. doi:10.1023/A:1015125031829

[6] Trofimova SV, Khavinson VKh. Effectiveness of bio-regulators in the treatment of diabetic retinopathy. Vestn Oftalmol. 2001;117(3):11-4. https://pubmed.ncbi.nlm.nih.gov/11521426/

The information presented in this article is for educational and research purposes only, intended for laboratory professionals, researchers and collaborators. This content does not constitute medical or clinical advice.

Most short peptides studied in bioregulation carry four amino acids or more. Chonluten carries three.

That minimal structure — glutamic acid, aspartic acid, glycine, sequenced as Glu-Asp-Gly — has drawn research attention across four decades. Not because it activates receptors in the classical pharmacological sense, but because it appears to operate closer to the source: the gene promoter regions that govern what proteins cells produce in the first place.

This profile covers what published research has observed about Chonluten, how it fits within the Khavinson bioregulator framework, and where laboratory investigations have directed focus.

What Is Chonluten?

Chonluten is a synthetic tripeptide bioregulator with the amino acid sequence Glu-Asp-Gly, also catalogued in the research literature as tripeptide T-34 or the EDG peptide. It carries a molecular weight of approximately 319.27 g/mol.

The compound belongs to the class of synthetic Cytogen bioregulators — short peptide analogs developed to reproduce the biological signaling activity of their naturally derived counterparts. Understanding where Chonluten sits within this classification requires some background on what peptide bioregulators are and how bioregulators differ from conventional research peptides as a category.

Its natural-extract counterpart is Bronchogen, isolated from bronchial tissue. Chonluten is the synthesized form — produced from constituent amino acids to reproduce the active signaling sequence in a precisely defined molecular structure.

Related Product: Buy Chonluten peptide for in vitro laboratory research applications.

The Khavinson Bioregulator Model

The research framework behind Chonluten traces to work begun in the early 1970s by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. That body of research established a class of short peptides isolated from specific animal organs, each displaying preferential biological activity in the corresponding tissue type.

The compounds were called cytomedines — tissue-derived regulatory peptides hypothesized to modulate cellular differentiation, proliferation, and intercellular signaling. Among the compounds characterized through this program was a tripeptide derived from bronchial epithelial cells: what would become Chonluten.

Epitalon, derived from pineal gland tissue, and Vilon, a dipeptide with immune system activity, were characterized through the same research program. The tissue-specific profiles of these compounds became a defining feature of the bioregulator model.

How Short Peptides Interact with Gene Promoters

The proposed mechanism separating Khavinson-class bioregulators from conventional receptor-based compounds is their apparent interaction with DNA directly.

According to a 2021 systematic review published in Molecules by Khavinson and colleagues, short peptides of 2–7 amino acid residues can penetrate cellular and nuclear membranes, interact with nucleosome histone proteins, and bind to specific sequences in gene promoter regions.^[1]

Rather than activating a surface receptor and initiating a downstream cascade, these peptides appear to interact with transcriptional architecture at the source — modulating which genes get expressed without introducing an external molecular signal.

The review documents this across multiple compounds. Chonluten, as a Glu-Asp-Gly tripeptide carrying acidic residues (glutamic acid, aspartic acid), falls within the structural class examined in these DNA-binding analyses.

DNA methylation status was also identified in the review as a variable that short peptides can both read and potentially influence — a finding with implications for how researchers model epigenetic regulation in aged or stressed cell populations.

Chonluten in Bronchopulmonary Research Models

Preclinical and in vitro investigations position Chonluten’s primary research activity in bronchopulmonary tissue. Bronchial epithelial and alveolar cell models have been used to examine how the compound interacts with pathways tied to mucosal homeostasis and inflammatory gene regulation.

Antioxidant Gene Pathway Observations

Research literature on Khavinson bronchial bioregulators identifies antioxidant gene networks as a primary area of observed modulation.^[2]

Genes associated with superoxide dismutase (SOD) activity and glutathione-related regulatory pathways appear in discussions of how short peptide bioregulators affect oxidative conditions in bronchial epithelial models.

The proposed mechanism: peptide interaction with the promoter regions of genes encoding these antioxidant proteins, altering their transcriptional availability in stressed cell environments. The result, as framed in the bioregulator literature, is a shift in redox balance rather than a direct antioxidant chemical contribution.

Inflammatory Signaling Pathway Activity

In preclinical respiratory models, Chonluten has been linked to changes in the expression of genes tied to inflammatory mediator production.^[2]

c-Fos — an immediate early gene involved in cell proliferation and inflammatory signaling — and COX-2 pathway-related gene products appear in its documented research profile. The pattern described in available literature: normalization of gene expression rather than broad suppression or stimulation.

For in vitro airway research, this positions Chonluten as a tool for studying mucosal inflammatory gene pathways independently of systemic immune confounders.

Chonluten in Immune Cell Models

The most detailed published investigation of Chonluten at the cellular level is a 2022 study by Avolio, Martinotti, Khavinson, and colleagues, published in International Journal of Molecular Sciences. The study used the THP-1 monocytic leukemia cell line — capable of differentiating into macrophages — to evaluate five Khavinson peptides across inflammatory and proliferative signaling parameters.^[3]

Chonluten produced several observations distinct from the other four peptides tested alongside it.

TNF Modulation and the Tolerance Mechanism

When THP-1 monocytes were incubated with Chonluten, a moderate release of TNF was detected — a profile the researchers linked to a TNF tolerance mechanism that attenuates further inflammatory response.^[3]

This differs from a straightforward suppressive effect. The mild TNF signal appeared to prime cells toward reduced inflammatory reactivity — a finding the authors associate with Chonluten’s origin in bronchogenic tissue, where monocyte recruitment is active during inflammatory extension into bronchial and alveolar compartments.

In terminally differentiated macrophages exposed to lipopolysaccharide (LPS), Chonluten suppressed both TNF-α and IL-6 expression alongside the other Khavinson peptides in the study. IL-6, a primary driver of acute phase inflammatory signaling, showed consistent downregulation across the peptide panel.

STAT1 Phosphorylation and Nuclear Translocation

Confocal microscopy in the same study confirmed that Chonluten activated STAT1 phosphorylation in differentiated macrophages.^[3]

Phosphorylated STAT1 molecules translocated into cell nuclei — a process the researchers described as occurring through a receptor-independent mechanism, without detectable modulation of IFN-α production. This observation aligns with the broader Khavinson model: peptide-mediated interaction with intracellular transcriptional machinery that bypasses canonical cytokine-receptor pathways.

STAT3 — a transducer involved in IL-6 signaling and acute inflammatory response — showed attenuation rather than amplification when macrophages were co-treated with peptides and LPS. The STAT3 pattern is consistent with the anti-inflammatory orientation seen across the cytokine data.

Cell Adhesion Reduction in Endothelial Assays

The study also examined whether peptide pretreatment affected monocyte adhesion to activated endothelial cells.^[3]

Using LPS-activated umbilical vein endothelial cells (HUVECs) as the adhesion substrate, Chonluten-pretreated THP-1 monocytes showed a measurable reduction in adhesion relative to untreated controls. Cell adhesion to activated endothelium is a documented step in inflammatory cell recruitment — and the reduction observed across most peptides in this assay has relevance to in vitro inflammatory recruitment modeling.

Gastrointestinal Research Models

Chonluten’s secondary research area is the gastrointestinal tract — specifically models examining oxidative stress responses in gastric mucosal tissue.

Oxidative Stress Protein Regulation

Published documentation on Chonluten in gastrointestinal contexts focuses on two protein targets: c-Fos and heat shock protein HSP70.

Both appear in the context of cellular stress response and inflammatory-proliferative balance. c-Fos functions as an immediate early gene. HSP70 is a heat shock protein involved in protein folding, stress protection, and the regulation of apoptotic pathways under oxidative conditions.

In gastric mucosal cell models, Chonluten has been observed in research documentation to modulate the expression of genes producing these proteins — framed as normalization of disrupted molecular and cellular processes rather than stimulation or blanket suppression.^[4]

In Vitro Research Applications

Research Access and Compound Quality

For laboratories working with Chonluten, compound integrity shapes the reliability of experimental outcomes.

BioLongevity Labs supplies Chonluten peptide for in vitro research use with purity verified through independent triple third-party testing from three separate certified laboratories. Certificates of analysis are available prior to purchase at biolongevitylabs.com/all-coas.

All products are manufactured in USA GMP-compliant facilities and are supplied strictly for research use only — not for personal or veterinary consumption.

Researchers working with Chonluten in bronchopulmonary gene regulation studies, inflammatory pathway modeling, or Khavinson bioregulator research can access the compound through the BioLongevity Labs Chonluten product page.

References

1. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. MDPI AG; 2021. https://doi.org/10.3390/molecules26227053
2. A COMPREHENSIVE REVIEW OF THE TOXIC EFFECTS OF MERCURY IN DENTAL AMALGAM FILLINGS ON THE ENVIRONMENT AND HUMAN HEALTH. 2016.
3. Avolio F, Martinotti S, Khavinson VKh, Esposito JE, Giambuzzi G, Marino A, et al. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. MDPI AG; 2022. https://doi.org/10.3390/ijms23073607
4. Khavinson VKh, Lin’kova NS, Dudkov AV, Polyakova VO, Kvetnoi IM. Peptidergic Regulation of Expression of Genes Encoding Antioxidant and Anti-Inflammatory Proteins. Springer Science and Business Media LLC; 2012. https://doi.org/10.1007/s10517-012-1590-2

The information presented in this article is for educational and research purposes only, intended for laboratory professionals, researchers and collaborators. This content does not constitute medical or clinical advice.

Amylin research has historically centered on pramlintide, the first synthetic amylin analog to reach clinical evaluation. Cagrilintide represents a structurally distinct approach — a lipidated, long-acting analog engineered to address pramlintide’s serum stability limitations and expand the receptor-targeting profile available to researchers.

This article walks through cagrilintide’s molecular design, its binding profile across amylin and calcitonin receptor subtypes, and what preclinical and study-model data reveal about its pharmacological activity. All content is framed for laboratory and preclinical research contexts.

What Is Amylin and Why It Matters in Metabolic Research

Amylin is a neuroendocrine polypeptide hormone co-secreted with insulin by pancreatic beta cells in response to nutrient intake.

Its primary relevance to metabolic research lies in its satiety signaling role. Amylin targets multiple regions of the central nervous system, with the area postrema (AP) — a circumventricular organ in the caudal hindbrain — identified as its primary site of action in preclinical models.

From the AP, signal propagation extends through the nucleus of the solitary tract (NTS) and the lateral parabrachial nucleus (LPBN), circuits associated with appetite regulation and energy balance in rodent research.

Amylin also acts on agouti-related peptide (AgRP) and pro-opiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus, where it may contribute to energy expenditure modulation independent of the AP pathway.

Native amylin is prone to fibril formation and carries a short serum stability period — pharmacokinetic limitations that drove the development of engineered analogs including pramlintide and, more recently, cagrilintide.

Related Product: Buy Cagrilintide for in vitro laboratory research applications.

What is Cagrilintide?

Cagrilintide (also designated AM833) was developed using structure-activity relationship modeling, with the objective of producing a long-acting amylin analog with retained AMY3R affinity and reduced fibrillation risk.

Several targeted modifications distinguish it from native amylin and pramlintide.

• Lipidation: A C20 fatty acid chain attached at the N-terminus supports reversible albumin binding — a well-documented mechanism for extending the serum stability period of peptide hormones. Cagrilintide’s serum stability period has been measured at approximately 159–195 hours in study models, supporting once-weekly compound application intervals.
• Proline substitutions (25P/28P/29P): Analogous to rat amylin, these substitutions reduce beta-sheet propensity and inhibit fibril formation, a defining limitation of native amylin.
• Salt bridge mutations (14E/17R): These mutations are expected to stabilize the central helix of the peptide through intramolecular salt bridge formation.
• C-terminal proline: Added to selectively increase potency at the calcitonin receptor (CTR), completing cagrilintide’s non-selective DACRA receptor profile.

For researchers working in peptide modification and lipidation, the structural vocabulary underlying these modifications is outlined in our peptide glossary.

Receptor Binding Profile: AMY1R, AMY3R, and CTR

Amylin binds to heteromeric receptor complexes formed by the calcitonin receptor (CTR) combined with receptor activity-modifying proteins 1, 2, or 3 (RAMP1–3), generating three distinct amylin receptor subtypes: AMY1R, AMY2R, and AMY3R.

CTR alone carries higher affinity for calcitonin. Combined with RAMP subunits, it gains substantially greater affinity for amylin.

Cagrilintide is classified as a non-selective agonist across AMYRs and CTR — a DACRA. Receptor pharmacology research published in the Journal of Pharmacology and Experimental Therapeutics characterized cagrilintide’s pharmacological profile across 25 endpoints in cell lines expressing primate, rat, and mouse receptor variants, including HEK293 cells transfected with CTR and AMY3R constructs. Cagrilintide activated AMY1R and CTR with roughly equivalent potency across species in cAMP assays.

This non-selective binding pattern distinguishes it from AMY1R-selective analogs in development and from pramlintide’s more restricted receptor profile.

How Cagrilintide Differs From Salmon Calcitonin in In Vitro Models

Salmon calcitonin (sCT) is the most commonly used reference compound for DACRA research, sharing cagrilintide’s receptor targets.

The key pharmacodynamic distinction lies in receptor residence time. In vitro receptor data show cagrilintide dissociates from all receptor subtypes within 3–6 minutes, while sCT residence times range from 45–60 minutes across the same receptors.

This kinetic difference produces distinct downstream cAMP signaling profiles. Cagrilintide’s cAMP activation in cell assays returns to baseline within a few hours post-application, while sCT maintains a sustained cAMP response. The contrasting body weight outcomes observed between these two compounds in rodent models have been attributed in part to these receptor dynamics.

Preclinical Receptor Research: What In Vivo Models Reveal

A 2025 study published in eBioMedicine by Carvas et al. (University of Zurich, in consortium with the Novo Nordisk Foundation) provides the most detailed in vivo mechanistic data currently available for cagrilintide’s receptor specificity.

Using RAMP1/3 double-knockout (KO) mice on a high-fat diet, the study compared subchronic treatment outcomes in wild-type and KO animals over a 21-day protocol.

Key observations from the study:

• Cagrilintide produced a sustained body mass reduction in wild-type mice (−3.4 g by day 21, P < 0.005) with no body mass effect in RAMP1/3 KO animals
• The body mass reduction in wild-type mice was accompanied by a reduction in relative fat mass and maintenance of relative lean mass — a pattern absent in KO animals
• Plasma leptin levels decreased approximately 2-fold in wild-type cagrilintide-treated mice versus vehicle-treated controls

These results confirm that cagrilintide’s effects in these preclinical models are mediated through AMY1R and AMY3R rather than through independent CTR activation.

Area Postrema Neuronal Activation in Preclinical Models

The same study assessed neuronal activity using cFos immunostaining across the AP, NTS, and LPBN following acute compound application.

In wild-type mice, cagrilintide produced measurable cFos signal in AP, NTS, and LPBN neurons. In RAMP1/3 KO mice, AP cFos signal following cagrilintide application was reduced by 57% versus wild-type animals (P < 0.001).

A second cohort using RAMP1 KO, RAMP3 KO, and RAMP1/3 KO mice confirmed that cagrilintide-induced cFos activation in the AP was reduced across all single and double KO genotypes, pointing to both AMY1R and AMY3R as necessary components of the full neuronal activation response.

This receptor-specific mechanistic framework is directly relevant to laboratory research into amylin receptor pharmacology, GPCR signaling, and body composition modeling. For related in vitro contexts using metabolic peptides, our research overviews on AOD9604 and Tesamorelin cover adjacent preclinical research profiles.

Study Observations: Trial Data From Human Study Models

Cagrilintide is currently the subject of multiple Phase 2 and Phase 3 trials. The following summarizes study findings reported in peer-reviewed and congress-presented data, framed as observations from controlled study models.

Phase 2 — CagriSema in Type 2 Diabetes Study Populations (Lancet, 2023)

Frias et al. reported findings from a 32-week Phase 2 multicentre study in which participants received once-weekly co-administration of cagrilintide 2.4 mg and semaglutide 2.4 mg (CagriSema), cagrilintide alone, or semaglutide alone. Mean body weight change from baseline in the CagriSema group was −15.6%, versus −8.1% for cagrilintide monotherapy and −5.1% for semaglutide — an observation consistent with additive activity across two distinct receptor pathways.

Phase 3 — REDEFINE 2 (New England Journal of Medicine, 2025)

The REDEFINE 2 trial, published in the New England Journal of Medicine, evaluated CagriSema versus placebo in adults with overweight or obesity and type 2 diabetes across 12 countries. Estimated mean body weight change at 68 weeks was −13.7% in the CagriSema group versus −3.4% with placebo (estimated difference −10.4 percentage points, 95% CI −11.2 to −9.5, P < 0.001).

Phase 3 — REDEFINE 1 Monotherapy Sub-Analysis (EASD Congress, 2025)

A sub-analysis from the REDEFINE 1 trial — representing the first Phase 3 data for a long-acting amylin analog as monotherapy — reported an average body weight reduction of 11.8% with cagrilintide 2.4 mg versus 2.3% with placebo at 68 weeks, in a population of adults with obesity or overweight without type 2 diabetes. Additionally, 31.6% of participants in the cagrilintide group reached more than 15% body weight reduction versus 4.7% with placebo.

For broader context on where amylin analog research sits within the current metabolic peptide field, see BLL’s 2026 Peptide Industry Report.

Potential In Vitro Research Applications

All BioLongevity Labs compounds are supplied for in vitro laboratory research only.

Cagrilintide in the Research Landscape

Cagrilintide occupies a well-defined position among amylin-class compounds.

Its extended serum stability period, non-selective DACRA receptor profile, and precisely characterized molecular modifications make it one of the most thoroughly studied amylin analogs currently in active Phase 3 evaluation.

For laboratories researching GPCR pharmacology, amylin pathway signaling, or lipidated peptide behavior in preclinical models, cagrilintide’s expanding body of in vitro and in vivo data offers a well-sourced mechanistic reference.

BioLongevity Labs supplies research-grade peptides and bioregulators with triple third-party testing and full COA documentation for every batch. Browse the full peptide catalog or review available Certificates of Analysis at biolongevitylabs.com/all-coas/.

References

1. Fletcher, M. M., Keov, P., Truong, T. T., Mennen, G., Hick, C. A., Zhao, P., Furness, S. G. B., Kruse, T., Clausen, T. R., Wootten, D., & Sexton, P. M. (2021). AM833 is a novel agonist of calcitonin family G protein-coupled receptors: Pharmacological comparison with six selective and nonselective agonists. Journal of Pharmacology and Experimental Therapeutics, 377(3), 417–440. https://doi.org/10.1124/jpet.121.000567
2. Carvas, A. O., Leuthardt, A., Kulka, P., Lommi, G., Hassan, S., Coester, B., Lundh, S., Pers, T., Secher, A., Raun, K., Lutz, T. A., & Le Foll, C. (2025). Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. eBioMedicine, 118, 105836. https://doi.org/10.1016/j.ebiom.2025.105836
3. Frias, J. P., Deenadayalan, S., Erichsen, L., Knop, F. K., Lingvay, I., Macura, S., Mathieu, C., Pedersen, S. D., & Davies, M. (2023). Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: A multicentre, randomised, double-blind, active-controlled, phase 2 trial. The Lancet, 402(10403), 720–730. https://doi.org/10.1016/S0140-6736(23)01163-7
4. REDEFINE 2 Study Group. (2025). Cagrilintide–semaglutide in adults with overweight or obesity and type 2 diabetes. New England Journal of Medicine. Advance online publication. https://doi.org/10.1056/NEJMoa2502082
5. Novo Nordisk. (2025, September). Cagrilintide 2.4 mg monotherapy: Sub-analysis of the phase 3 REDEFINE 1 trial (NCT05567796) [Conference presentation]. European Association for the Study of Diabetes Annual Congress, Vienna, Austria.

The information presented in this article is for educational and research purposes only, intended for laboratory professionals, researchers and collaborators. This content does not constitute medical or clinical advice.

Most ACTH-derived peptides carry significant hormonal baggage. Semax was engineered specifically to strip that away.

Developed at the Russian Academy of Sciences in the 1980s, Semax isolates the neurotrophic effects of adrenocorticotropic hormone (ACTH) while leaving its cortisol-stimulating activity behind. That design decision — a deliberate structural separation — made it one of the most studied synthetic neuropeptides in preclinical neuroscience.

This article covers what Semax is, how it’s structured, what preclinical research shows about its activity, and where in vitro investigation is currently focused.

What is Semax Peptide?

Semax is a synthetic heptapeptide with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP).

It is an analog of ACTH(4-10), the N-terminal fragment of adrenocorticotropic hormone. Unlike native ACTH, Semax produces no corticotropic activity — it does not stimulate cortisol secretion or interact with the adrenal axis in standard preclinical models.

Featured Product: Buy N-Acetyl Semax Amidate for in vitro laboratory research applications.

Origins and structural design

ACTH’s capacity to influence cognition and neurological function has been documented since the 1950s. Researchers at the Russian Academy of Sciences spent decades attempting to isolate those neurotrophic properties from the hormonal effects.

Semax was the result. The ACTH(4-7) fragment — Met-Glu-His-Phe — was retained for its neurotrophic activity, while the hormonal sequence was excluded. The compound was first described in scientific literature in 1991 and has since been studied across a range of preclinical neurological models.

The role of the Pro-Gly-Pro tripeptide

The PGP (Pro-Gly-Pro) sequence at Semax’s C-terminus was added to address a stability problem.

The ACTH(4-7) fragment alone degrades rapidly in serum due to peptidase activity. Adding the PGP tripeptide confers resistance to enzymatic breakdown, extending the compound’s activity window in preclinical models from roughly 15 minutes to approximately 20 to 24 hours in animal studies. Semax has a molecular weight of 813.92 Daltons and is classified as a melanocortin-related peptide.

Semax Mechanisms in Preclinical Research

Semax doesn’t appear to work through a single pathway. Preclinical research has identified at least three distinct mechanistic routes — BDNF modulation, genome-wide gene expression changes, and melanocortin receptor interactions — each investigated independently across multiple study designs.

BDNF and TrkB upregulation

The most consistently documented effect of Semax in preclinical models is its modulation of brain-derived neurotrophic factor (BDNF) and its signaling receptor, TrkB.

Dolotov et al. (2006) found that a single intranasal Semax application (50 μg/kg) produced a 1.4-fold increase in BDNF protein levels alongside a 3-fold increase in exon III BDNF mRNA in rat hippocampus, with accompanying TrkB phosphorylation. ^[1]

A related study from the same group in the Journal of Neurochemistry identified specific, calcium-dependent binding sites for Semax in rat basal forebrain tissue, with BDNF protein levels rising within 3 hours of intranasal exposure at both 50 and 250 μg/kg concentrations.^[2]

These findings suggest Semax interacts with specific binding sites in the basal forebrain — which may at least partly account for the BDNF changes observed downstream.

Genome-wide gene expression modulation

A 2014 genome-wide transcriptomics study in BMC Genomics by Medvedeva et al. examined Semax’s effect on rat brain cortex following permanent middle cerebral artery occlusion (pMCAO). Semax significantly modulated immune-response gene expression — particularly genes encoding chemokines and immunoglobulins — at both 3h and 24h post-occlusion. Twenty-four genes related to vascular function (endothelial migration, smooth muscle cell activity, vasculogenesis) also showed altered expression.^[3]

More recently, Filippenkov et al. (2024) used RNA-Seq to show that Semax compensated for ischemia-disrupted gene expression profiles in rat frontal cortex at 24 hours after transient MCAO, restoring expression of 1,171 genes associated with immune and neurosignaling pathways.^[4]

Melanocortin receptor interactions

Semax interacts with melanocortin receptors, though the precise pharmacology is still being characterized.

Available in vitro and in vivo data indicate Semax acts as a competitive antagonist or partial agonist at MC4 and MC5 receptors, without apparent interaction at MC3. Semax has also been shown to inhibit enkephalinase enzymes — proteins responsible for the degradation of endogenous regulatory peptides — at IC50 concentrations around 10 μM. This property is shared with Selank, a structurally related research peptide. For a side-by-side comparison of these compounds, see our Selank vs. Semax research overview.

Semax in Preclinical Research Models

Researchers have applied Semax across several distinct preclinical model categories, each probing different aspects of its mechanistic profile.

Cerebral ischemia and stroke models

A 2009 study by Dmitrieva et al. published in Cellular and Molecular Neurobiology examined neurotrophin mRNA expression in rat cortex following pMCAO. Semax activated transcription of BDNF, TrkC, and TrkA at 3h post-occlusion, and NGF at 24h — selectively in ischemic tissue rather than sham-operated controls.^[5]

At the protein level, Sudarkina et al. (2021) used immunodetection in a transient MCAO model to show that Semax produced upregulation of CREB (a recovery-associated protein) and downregulation of MMP-9, c-Fos, and JNK in both ipsilateral cortex and subcortical structures at 24h.^[6]

In a clinical observational study, Gusev et al. (2018) enrolled 110 post-ischemic stroke patients and reported that Semax exposure was associated with increased plasma BDNF levels throughout the observation period, with positive correlations between BDNF levels and Barthel index scores.^[7]

Chronic stress models

Inozemtseva et al. (2024) published in the European Journal of Pharmacology examined Semax in a chronic unpredictable stress (CUS) model using male Sprague-Dawley rats. Daily intraperitoneal Semax (60 nmol/kg) reversed CUS-induced anhedonia, attenuated body weight suppression, reduced adrenal hypertrophy, and restored hippocampal BDNF levels. The authors proposed that Semax’s activity at ACTH(4-10) receptors and the melanocortin system may modulate HPA axis regulation in stress conditions.^[8]

Neurodegenerative research

Semax has also been explored in optic nerve and broader neurodegenerative contexts — an area with overlap in our earlier coverage of peptides for ocular and retinal research. The peptide’s documented BDNF-elevating activity has made it a subject of interest in models where neurotrophin support is mechanistically relevant.

In vitro research applications

All applications are preclinical or in vitro. Semax supplied by BioLongevity Labs is for research use only.

How Semax compares to Selank

Semax shares some structural and pharmacological territory with Selank, another ACTH-related synthetic peptide.

Both are derived from the ACTH melanocortin peptide family, both inhibit enkephalinase enzymes, and both have been studied across CNS-related preclinical models. The primary divergence is mechanistic emphasis — Selank research has been oriented more toward immunomodulatory and anxiolytic pathways, while Semax research has concentrated heavily on BDNF signaling and stroke-related neuroprotection.

Sourcing Semax for in vitro research

Researchers requiring Semax for laboratory use need a supplier that documents what they’re shipping.

BioLongevity Labs provides research-grade Semax with triple third-party analytical verification from three independent certified laboratories. Each batch is confirmed by HPLC purity analysis, LC-MS molecular verification, and sterility and endotoxin testing, with COA documentation available prior to purchase.

All BioLongevity Labs peptides are manufactured in a U.S. GMP-certified facility and shipped with complete analytical documentation — a baseline requirement for protocol reproducibility. Orders placed before 12pm PT ship same-day, with free shipping on orders over $400.

Semax from BioLongevity Labs is supplied strictly for research use.

References

1. Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, et al. Semax, an analog of ACTH(4–10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Elsevier BV; 2006. https://doi.org/10.1016/j.brainres.2006.07.108
2. Dolotov OV, Karpenko EA, Seredenina TS, Inozemtseva LS, Levitskaya NG, Zolotarev YA, et al. Semax, an analogue of adrenocorticotropin (4–10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Wiley; 2006. https://doi.org/10.1111/j.1471-4159.2006.03658.x
3. Medvedeva EV, Dmitrieva VG, Povarova OV, Limborska SA, Skvortsova VI, Myasoedov NF, et al. The peptide Semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. Springer Science and Business Media LLC; 2014. https://doi.org/10.1186/1471-2164-15-228
4. Filippenkov IB, Shpetko YYu, Stavchansky VV, Denisova AE, Gubsky LV, Andreeva LA, et al. ACTH-like peptides compensate rat brain gene expression profile disrupted by ischemia a day after experimental stroke. MDPI AG; 2024. https://doi.org/10.3390/biomedicines12122830
5. Dmitrieva VG, Povarova OV, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Springer Science and Business Media LLC; 2009. https://doi.org/10.1007/s10571-009-9432-0
6. Sudarkina OYu, Filippenkov IB, Stavchansky VV, Denisova AE, Yuzhakov VV, Sevan’kaeva LE, et al. Brain protein expression profile confirms the protective effect of the ACTH(4–7)PGP peptide (Semax) in a rat model of cerebral ischemia-reperfusion. MDPI AG; 2021. https://doi.org/10.3390/ijms22126179
7. Gusev EI, Martynov MYu, Kostenko EV, Petrova LV, Bobyreva SN. The efficacy of Semax in the treatment of patients at different stages of ischemic stroke. Media Sphere Publishing House; 2018. https://doi.org/10.17116/jnevro20181183261-68
8. Inozemtseva LS, Yatsenko KA, Glazova NY, Kamensky AA, Myasoedov NF, Levitskaya NG, et al. Antidepressant-like and antistress effects of the ACTH(4–10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. Elsevier BV; 2024. https://doi.org/10.1016/j.ejphar.2024.177068

The information presented in this article is for educational and research purposes only, intended for laboratory professionals, researchers and collaborators. This content does not constitute medical or clinical advice.

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences.

Its amino acid sequence — Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP) — is derived from tuftsin, an endogenous immunomodulatory tetrapeptide, with a three-residue extension added to improve metabolic stability.

What draws researchers to Selank isn’t a single mechanism. Three distinct pathways have been studied in preclinical models: GABAergic modulation, neurotrophin regulation, and immunomodulatory activity inherited from its tuftsin lineage.

This article covers each of those mechanisms, the study models where they’ve been examined, and what the published literature says about how they interact.

For research use only. All products and compounds discussed are intended strictly for in vitro and preclinical laboratory research.

What Is Selank Peptide?

Selank belongs to a class of regulatory peptides developed from endogenous sequences. Its design — extending tuftsin’s four-residue backbone with Pro-Gly-Pro — gave researchers a compound with longer serum stability than the native tetrapeptide, making it more tractable for laboratory study.

It is also known by its experimental designation TP-7.

Origins and Development

Tuftsin (Thr-Lys-Pro-Arg) is a naturally occurring tetrapeptide cleaved from the Fc region of immunoglobulin G. It was identified as an immunostimulant in the 1970s and has since been studied for anti-inflammatory, antimicrobial, and antitumor activity, as reviewed in Siebert et al. (2017).^[1]

Selank was synthesized by appending a Pro-Gly-Pro tripeptide to tuftsin’s C-terminus. That modification significantly extends the compound’s resistance to enzymatic degradation compared to the parent molecule — a property relevant for any researcher designing time-course studies.

Structural Profile

Selank carries the sequence TKPRPGP across seven amino acid residues, with a molecular formula of C₃₃H₅₇N₁₁O₉ and a molecular weight of approximately 751.9 Da.

Understanding how the polarity and charge distribution of those residues affects binding behavior is worth reviewing alongside foundational material on polar and nonpolar amino acids before designing binding or stability assays.

Lyophilized Selank is stable for extended periods under proper cold storage conditions, making it suitable for multi-experiment research protocols.

Featured Product: Buy N-Acetyl Selank for in vitro laboratory research applications.

Selank’s Three Studied Research Mechanisms

Selank occupies an unusual position in neuropeptide research: it has been examined across three mechanistic axes that are largely independent in the literature. Most papers address one of them in depth.

The three are GABAergic system modulation, BDNF-related neurotrophin regulation, and immunomodulatory activity inherited from tuftsin.

GABAergic System Modulation

The most extensively studied mechanism involves Selank’s interaction with the GABAergic system — the primary inhibitory neurotransmitter pathway in the mammalian central nervous system.

Volkova et al. (2016) analyzed changes in the expression of 84 genes involved in neurotransmission in rat frontal cortex tissue. One hour after Selank application at 300 µg/kg, 45 genes showed measurable expression changes. At the three-hour mark, 22 genes remained altered. The pattern of change showed positive correlation with GABA-treated controls, pointing toward allosteric modulation of GABA-A receptor activity as a probable mechanism.^[2]

Vyunova et al. (2018) examined that allosteric interaction directly using radioligand-receptor methods. Selank was shown to affect [³H]GABA binding in a concentration-dependent manner consistent with positive allosteric modulation of GABA-A receptors — a mechanistically distinct profile from classical benzodiazepines despite some behavioral overlap in anxiety models.^[3]

A follow-up study by Filatova et al. (2017) tested Selank in IMR-32 neuroblastoma cells alongside GABA and olanzapine. Selank alone produced no direct changes in GABAergic gene mRNA levels in that cell line. When combined with GABA, Selank nearly fully suppressed the gene expression changes GABA produced on its own. The authors interpreted this as evidence that Selank affects GABA receptor interactions rather than acting as a direct transcriptional modulator — a distinction with implications for how labs design mechanistic assays.^[4]

BDNF and Neurotrophin Regulation

Brain-derived neurotrophic factor (BDNF) is a well-characterized regulator of synaptic plasticity and neuronal survival. Selank’s influence on BDNF expression has been studied in rat brain tissue across multiple models.

Kolik et al. (2019) examined BDNF content in the hippocampus and prefrontal cortex of rats exposed to chronic ethanol, followed by seven-day Selank application. Selank prevented the ethanol-induced increase in BDNF content in both brain regions in ex vivo analysis. The authors concluded that neurotrophin pathways related to BDNF production are involved in Selank’s mechanism of action — though the directionality of that involvement appears context-dependent, with BDNF modulation differing between basal and stress-exposed conditions.^[5]

Earlier intranasal application studies (referenced in the Filatova and Kolik papers) had established that Selank can regulate BDNF expression in the rat hippocampus, which led to the neuroplasticity-related research focus seen in subsequent work.

For laboratories studying neurotrophin biology, this BDNF-modulatory profile makes Selank a potentially useful tool compound in models examining synaptic signaling or memory-related endpoints.

Immunomodulatory Activity

Selank inherits immunomodulatory properties from tuftsin — and researchers have begun characterizing how that activity manifests at the gene expression level.

Kolomin et al. (2013) examined the temporal dynamics of inflammation-related gene expression in mouse spleen following a single intraperitoneal injection of Selank at 100 µg/kg. C3 mRNA levels dropped approximately threefold within 30 minutes of application. Wave-like alterations in Casp1, Il2rg, and Xcr1 expression were observed across the 90-minute observation window. Notably, Selank’s short fragment Gly-Pro produced similar expression profiles for most genes tested — pointing to the dipeptide’s contribution to the full compound’s immunomodulatory effect.^[6]

This immune axis is where Selank’s research profile diverges most sharply from structurally similar neuropeptides. Researchers focused on Th1/Th2 balance, complement regulation, or cytokine signaling may find Selank a useful comparator compound alongside immune-focused peptides like thymulin.

How Selank Compares to Related Research Peptides

Selank is rarely studied in isolation from Semax, a structurally unrelated neuropeptide developed at the same institute around the same period.

Both compounds share the property of inhibiting enzymes responsible for breaking down enkephalins and other endogenous regulatory peptides. That shared activity on enkephalin metabolism creates some mechanistic overlap — but the two peptides differ in their amino acid sequences, receptor targets, and documented gene expression signatures.

Selank vs. Semax

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is an ACTH analog, not a tuftsin derivative. Its primary research focus has been neuroprotection, cognitive function, and BDNF upregulation — with a body of literature that is largely separate from Selank’s GABAergic and immunomodulatory work.

The two peptides are sometimes placed in the same experimental battery precisely because their mechanisms differ: using both allows researchers to isolate specific pathway contributions in complex behavioral or cellular models.

For a detailed breakdown of how the two compounds compare structurally and mechanistically, see the Selank vs. Semax comparison.

Selank in Laboratory Research Settings

The breadth of Selank’s studied mechanisms has resulted in its use across a range of experimental contexts — from in vitro gene expression work to ex vivo brain tissue analysis to preclinical stress models.

The table below summarizes the primary research areas represented in the published literature.

Research-Grade Selank: What to Look For

Quality varies across suppliers, and the mechanistic specificity of Selank research makes purity non-negotiable.

For in vitro or ex vivo work, any contaminant at the peptide level can produce confounding signal — particularly in gene expression assays where the compound’s effects are measured at very low concentrations.

Quality and Documentation Standards

BioLongevity Labs supplies Selank at greater than 99% purity, confirmed by HPLC and LC-MS analysis from three independent certified laboratories. Every batch ships with a full Certificate of Analysis documenting purity, molecular confirmation, and analytical methodology.

If you’re evaluating a supplier’s COA for the first time, the guide to reading peptide COAs covers what to look for and what gaps in documentation signal. For a broader overview of what third-party testing actually involves, see the third-party tested peptides resource.

Selank is available from BioLongevity Labs in lyophilized vial format, manufactured in a U.S. GMP-certified facility.

Closing Thoughts

Selank’s research profile is harder to summarize than most peptides precisely because it doesn’t reduce to a single mechanism.

The GABAergic work, the BDNF studies, and the immunomodulatory literature each represent distinct research threads developed mostly independently. Understanding how they relate — or whether they’re even causally linked — remains an open question in the field.

For labs designing experiments around anxiety models, neurotrophin biology, or immune signaling, that multi-axis profile is what makes Selank worth understanding in depth before committing to an experimental design.

Researchers sourcing Selank for in vitro studies can review documentation and place orders through the BioLongevity Labs Selank product page. All products are for research use only.

Research Use Only Disclaimer: All products and compounds discussed in this article are intended strictly for in vitro and preclinical laboratory research purposes. Researchers are responsible for complying with all applicable regulations in their jurisdiction.

References

1. Siebert, A., Gensicka-Kowalewska, M., Cholewinski, G., & Dzierzbicka, K. (2017). Tuftsin – Properties and Analogs. In Current Medicinal Chemistry (Vol. 24, Issue 34). Bentham Science Publishers Ltd. https://doi.org/10.2174/0929867324666170725140826
2. Volkova, A., Shadrina, M., Kolomin, T., Andreeva, L., Limborska, S., Myasoedov, N., & Slominsky, P. (2016). Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. In Frontiers in Pharmacology (Vol. 7). Frontiers Media SA. https://doi.org/10.3389/fphar.2016.00031
3. Vyunova, T. V., Andreeva, L., Shevchenko, K., & Myasoedov, N. (2018). Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. In Protein & Peptide Letters (Vol. 25, Issue 10, pp. 914–923). Bentham Science Publishers Ltd. https://doi.org/10.2174/0929866525666180925144642
4. Filatova, E., Kasian, A., Kolomin, T., Rybalkina, E., Alieva, A., Andreeva, L., Limborska, S., Myasoedov, N., Pavlova, G., Slominsky, P., & Shadrina, M. (2017). GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. In Frontiers in Pharmacology (Vol. 8). Frontiers Media SA. https://doi.org/10.3389/fphar.2017.00089
5. Kolik, L. G., Nadorova, A. V., Antipova, T. A., Kruglov, S. V., Kudrin, V. S., & Durnev, A. D. (2019). Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. In Bulletin of Experimental Biology and Medicine (Vol. 167, Issue 5, pp. 641–644). Springer Science and Business Media LLC. https://doi.org/10.1007/s10517-019-04588-9
6. Kolomin, T., Morozova, M., Volkova, A., Shadrina, M., Andreeva, L., Slominsky, P., Limborska, S., & Myasoedov, N. (2014). The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action. In Molecular Immunology (Vol. 58, Issue 1, pp. 50–55). Elsevier BV. https://doi.org/10.1016/j.molimm.2013.11.002

The information presented in this article is for educational and research purposes only, intended for laboratory professionals, researchers and collaborators. This content does not constitute medical or clinical advice.

Cortagen (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide derived from the directed analysis of Cortexin, a natural polypeptide extract of bovine cerebral cortex tissue.

What makes it worth attention in a research context is not just its neural tissue origins. It’s the genome-scale footprint it leaves behind — over 100 identified gene targets spanning multiple chromosomal regions, with activity in chromatin structure, oxidative balance, and immune signaling. That’s an unusually broad molecular profile for a four-residue peptide.

This article reviews what the current preclinical literature shows about cortagen peptide research, including its known mechanisms, experimental endpoints, and structural characteristics that make it a usable tool for in vitro work.

All products discussed are for research use only.

What is Cortagen? Molecular Profile and Origins

Cortagen has the amino acid sequence Ala-Glu-Asp-Pro and was obtained by directed synthesis based on the amino acid analysis of Cortexin, the natural brain cortex peptide preparation used clinically in Russia for its effects on memory, attention, and cortical processes.

The synthesis work was conducted at the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson, whose research group produced many of the short peptide bioregulators now studied in preclinical aging and CNS research.

The absence of disulfide bridges and reactive side chains makes Cortagen soluble across a broad pH range, which supports its use in aqueous buffer systems common in molecular biology protocols.

Related Product: Buy Cortagen peptide for laboratory research use.

How Cortagen Differs from Related Khavinson Peptides

Cortagen belongs to the same class of short bioregulators that includes Vilon (KE), Epithalon (AEDG), and Pinealon (Glu-Asp-Arg). These compounds share a research lineage — all derived from directed fractionation of tissue extracts from specific organs.

The comparison between Cortagen and Epithalon is worth noting for researchers designing experiments. The two peptides differ by a single amino acid at the C-terminus: Cortagen ends in Pro (proline), Epithalon in Gly (glycine). Despite that minimal structural difference, they show distinct tissue-preferential activity.

This tissue specificity pattern — with each short peptide showing activity preferential to the organ it was derived from — is documented across multiple Khavinson bioregulators in a 2021 systematic review in Molecules covering peptide-DNA interactions and transcriptional regulation.

Chromatin Remodeling and Transcriptome-Wide Gene Regulation

This is the most studied mechanistic dimension of cortagen peptide research, and it’s the angle that makes Cortagen genuinely interesting as a research reagent.

Short peptides at this size can penetrate cellular nuclei, interact with nucleosome components, and bind both single- and double-stranded DNA at specific promoter sequences. As documented in Khavinson et al.’s systematic review, these DNA-peptide interactions affect template-directed transcription, replication, and repair pathways.

For Cortagen specifically, the proposed mechanism involves decondensation of age-compressed heterochromatin — regions of the genome that become increasingly packed and transcriptionally silent as cells age. By interacting with chromatin architecture, Cortagen may reactivate genes repressed through that age-related compaction.

A parallel mechanism involves ribosomal RNA gene activation. In experimental models, Cortagen increased ribosomal gene activity and unpacked chromatin fibrils in a way consistent with restoration of transcriptional access to silenced loci.

Microarray Evidence — 110 Genes, 234 Chromosomal Regions

The most direct genome-scale data on Cortagen comes from a microarray study published in Neuroendocrinology Letters by Anisimov SV, Khavinson VKh, and Anisimov VN (2004).

The study analyzed expression of 15,247 transcripts in cardiac tissue from 6-month-old female CBA mice following five consecutive days of Cortagen exposure.

Comparative analysis against controls identified 234 clones with significant expression changes, matching 110 known genes across multiple functional categories. Maximum up-regulation reached +5.42 fold; maximum down-regulation was -2.86 fold.

The study also compared Cortagen’s cardiac expression profile against two other synthetic peptides (Vilon and Epithalon) and the pineal hormone melatonin. Both common and compound-specific effects were observed, which points to Cortagen having its own distinct gene regulatory signature rather than a generic response.

Cortagen and Oxidative Stress Markers

A separate line of preclinical evidence involves Cortagen’s observed effects on free-radical processes.

Research published in the Bulletin of Experimental Biology and Medicine reported that Cortagen exposure in rats reduced lipid peroxidation (LPO) product content and decreased oxidative modification of proteins. Antioxidant system activity in serum and cerebral cortex tissue was also affected.

These findings position Cortagen as a potential reagent in oxidative stress assay design — particularly for studies examining LPO markers, antioxidant enzyme behavior, or redox balance in neural cell systems.

Neural Research Applications — Ischemia and Neuroprotection Models

Beyond chromatin and oxidative stress, Cortagen has been studied in preclinical ischemia models.

A study by Zarubina IV and Shabanov PD published in Eksperimental’naia i Klinicheskaia Farmakologiia (2011, PMID: 21476278) examined Cortagen and Cortexin in a chronic brain ischemia rat model comparing animals with high vs. low hypoxia resistance.

Both compounds accelerated recovery of individual behavior following ischemic conditions. They also reduced excessive activation of lipid peroxidation and preserved antioxidant activity in brain tissue across both resistance phenotypes.

For researchers building ischemia-related in vitro protocols — particularly those examining neuronal resilience, oxidative burden, or behavioral recovery proxies in cellular models — this preclinical evidence gives Cortagen a measurable experimental context.

Immune Axis Observations — Interleukin-2 Expression

Cortagen’s research profile extends into neuroimmune territory, though this is a less-developed area of the literature compared to its chromatin and neuroprotection data.

Studies report that Cortagen increases the expression of the interleukin-2 (IL-2) gene in murine splenocytes. IL-2 is a cytokine with a broad role in immune cell proliferation and regulatory signaling, making this an area of interest for researchers examining the intersection of CNS peptides and immune function.

A broader epigenetic framing of this activity appears in work by Rubinskii AV, Linkova NS, Khavinson VK et al. (Advances in Gerontology, 2021), which positions AEDP alongside other Khavinson short peptides (AEDG, EDR, KED) as epigenetic regulators capable of modulating cytokine expression and stress-protective protein synthesis as part of adaptive responses.

This positions Cortagen as a potential research compound for studying peptide-driven immune-neural signaling — not a therapeutic implication, but a mechanistic one worth designing around.

Cortagen as an In Vitro Research Tool

Given the above, what does Cortagen actually offer in a lab setting?

Its structural characteristics make it workable. The linear four-residue sequence has a molecular weight around 430 g/mol, no disulfide bridges, and no reactive side chains — all of which support solubility, stability, and consistent behavior in aqueous buffer systems. It can diffuse effectively in biological systems without the steric complexity of larger peptides, making it a cleaner system for studying short peptide-to-macromolecule interactions.

Experimental endpoints where Cortagen has been used or proposed include:

• Gene expression profiling via microarray or qPCR in neural or cardiac cell lines
• Chromatin accessibility assays (ATAC-seq or DNase-seq equivalents in relevant cell types)
• Lipid peroxidation quantification (MDA, 4-HNE markers)
• Antioxidant enzyme activity (SOD, GPx) in cortex-derived cell models
• IL-2 expression measurement in immune cell co-culture systems
• Transcriptome-wide analysis comparing short bioregulator peptides

For researchers studying GHK-Cu or other gene-regulatory peptides, Cortagen offers a parallel with distinct tissue-specific parameters — useful for comparative experimental designs.

For a broader framing of the neuroepigenetic context in which Cortagen sits, the 2022 review by Ilina A and Khavinson V in the International Journal of Molecular Sciences covers ultrashort peptide mechanisms across DNA methylation, chromatin remodeling, histone modification, and non-coding RNA pathways.

Potential In Vitro Research Applications

Research-Grade Cortagen from BioLongevity Labs

BioLongevity Labs supplies Cortagen (AEDP) manufactured in a U.S. GMP-certified facility with triple third-party testing across three independent certified laboratories and a >99% purity guarantee.

Every batch ships with a full Certificate of Analysis. COAs are available for review before purchase at biolongevitylabs.com/all-coas/. If you want to know how to interpret what’s in a COA, the COA reading guide covers the key analytical markers to look for.

Cortagen from BioLongevityLabs is for laboratory and research use only.

References

1. Anisimov SV, Khavinson VKh, Anisimov VN. Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray. Neuro Endocrinol Lett. 2004;25(1-2):87-93. PMID: 15159690
2. Kozina LS. Effects of bioactive tetrapeptides on free-radical processes. Bull Exp Biol Med. 2007;143(6):744-6. DOI: 10.1007/s10517-007-0230-8
3. Zarubina IV, Shabanov PD. Cortexin and cortagen as correcting agents in functional and metabolic disorders in the brain in chronic ischemia. Eksp Klin Farmakol. 2011;74(2):8-15. PMID: 21476278
4. Rubinskii AV, Linkova NS, Chalisova NI, Noskin LA, Marchenko VN, Khavinson VK. Epigenetic regulation of adaptogenesis by pathology and aging. Adv Gerontol. 2021;34(1):10-17. PMID: 33993656
5. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of gene expression: a systematic review. Molecules. 2021;26(22). DOI: 10.3390/molecules26227053
6. Ilina A, Khavinson V, Linkova N, Petukhov M. Neuroepigenetic mechanisms of action of ultrashort peptides in Alzheimer’s disease. Int J Mol Sci. 2022;23(8). DOI: 10.3390/ijms23084259

The information presented in this article is for educational and research purposes only, intended for laboratory professionals, researchers and collaborators. This content does not constitute medical or clinical advice.

Vesugen represents a class of peptide bioregulators that operate through mechanisms distinct from conventional synthetic peptides.

This tripeptide consists of just three amino acids—lysine, glutamic acid, and aspartic acid—yet laboratory research demonstrates its capacity to modulate gene expression in both vascular endothelial cells and neuronal populations. The contrast between structural simplicity and regulatory complexity makes vesugen a compound of interest across multiple research domains.

Identified within the Khavinson bioregulator family, vesugen exhibits tissue-specific effects in vascular and nervous system cell cultures. Research applications span endothelial proliferation studies, neuronal differentiation protocols, and cellular aging models where gene expression patterns shift with senescence.

Molecular Structure and Bioregulator Classification

Vesugen carries the amino acid sequence Lys-Glu-Asp, frequently abbreviated as KED in research literature.

The molecular formula C₁₅H₂₆N₄O₈ corresponds to a molecular weight of 390.39 g/mol. This places vesugen among the ultrashort peptides that lack higher-order secondary or tertiary structures under standard laboratory conditions.

The peptide belongs to the Khavinson bioregulator family, a class of tissue-specific regulatory peptides originally derived from organ extracts. These compounds differ from synthetic peptides in their proposed mechanism—bioregulators are hypothesized to interact with gene regulatory elements rather than functioning primarily as receptor ligands.

Vesugen was initially isolated from vascular wall protein fractions. This tissue origin correlates with its demonstrated effects in vascular endothelial cell research, though subsequent studies have identified neuronal applications as well.

The linear structure facilitates reproducible biochemical interaction studies. Research groups investigating peptide-DNA and peptide-protein interactions use vesugen as a model compound for examining how short peptides may influence transcriptional activity.

Related Product: Buy Vesugen peptide for laboratory research use.

Vascular Endothelial Research Applications

Laboratory investigations into vesugen’s vascular effects center on endothelial cell function, which forms the foundation for vessel integrity and angiogenic responses.

Research models examine both normal endothelial maintenance and stress conditions including atherosclerosis and restenosis. Gene expression changes in these contexts provide measurable endpoints for vesugen’s regulatory activity.

Endothelial Proliferation and Ki-67 Regulation

Molecular docking studies demonstrate vesugen binding to the promoter region of the MKI67 gene, which encodes the Ki-67 proliferation marker.^[1]

Ki-67 expression decreases during endothelial cell aging in culture. Research using tissue-specific vascular endothelial cells from young versus aged animal models shows this proliferation marker declines as cells accumulate passages.

Vesugen application in these aging cell cultures increased Ki-67 protein expression. The peptide contacted the core promoter sequence located between -14 and +12 base pairs relative to the transcriptional initiation site.

The specific interaction occurred through a CATC sequence motif. This binding pattern suggests epigenetic regulation where short peptides modulate gene accessibility rather than activating traditional signal transduction cascades.

Concentrations in the nanomolar range produced measurable effects on Ki-67 levels. The dose-response relationship in endothelial cultures indicates receptor-independent mechanisms may drive these regulatory effects.

Vascular Integrity Markers

Research in atherosclerotic and restenotic endothelial models shows vesugen normalizes endothelin-1 expression patterns that become dysregulated under vascular stress.^[2]

Endothelin-1 levels increase during atherosclerosis progression and following vascular injury leading to restenosis. Vesugen application in these in vitro models reduced elevated endothelin-1 expression toward control levels.

The peptide also restored connexin expression in stressed endothelial cultures. Connexins form gap junctions that enable direct cell-to-cell communication, which becomes impaired in dysfunctional endothelium.

SIRT1 expression increased following vesugen exposure in vascular models. This NAD-dependent deacetylase participates in DNA repair pathways and metabolic regulation linked to cellular stress responses.^[2]

The combination of normalized endothelin-1, restored connexin communication, and increased SIRT1 suggests vesugen influences multiple pathways involved in endothelial homeostasis. These effects position the peptide as a research tool for investigating vascular stress and repair mechanisms.

Neuronal Differentiation and Neuroprotection Research

Vesugen’s applications extend beyond vascular biology into neuronal cell culture research.

Studies examining neurogenesis, synaptic plasticity, and neuronal aging use the peptide to modulate gene expression patterns associated with differentiation and survival. The neuronal effects appear mechanistically related to vascular applications through shared pathways of epigenetic regulation.

Neurogenesis Markers in Stem Cell Models

Research using periodontal ligament stem cells demonstrates vesugen increases expression of neuronal differentiation markers.^[3]

GAP43 (growth-associated protein 43) showed elevated expression in stem cell cultures exposed to vesugen. This protein implements neurotransmission mechanisms and neuroplasticity, serving as a marker of active neuronal growth.

Nestin, a neurofilament protein expressed in early neuronal precursors, also increased following vesugen application. The peptide alone produced these effects, though combination with other bioregulators showed additive responses.

Dendritic arborization measurements in induced neuronal cultures revealed vesugen promotes both primary process formation and total dendrite length. The peptide increased mushroom spine density by 20-27% in neurological models.^[4]

These morphological changes occurred without affecting mitochondrial activity or lysosomal function. The specificity suggests vesugen acts through gene expression modulation rather than broad metabolic effects.

Gene Expression in Aging Neurons

Studies using induced neurons derived from elderly donor fibroblasts show vesugen influences aging-associated gene expression patterns.^[4]

The peptide reduced oxidative DNA damage markers in these aging neuronal cultures. This protective effect on genomic integrity aligns with the SIRT1 upregulation observed in vascular models.

P16 and p21, genes associated with cellular senescence and cell cycle arrest, showed modulated expression in vesugen-treated aging neuron cultures. These senescence markers typically increase during cellular aging.^[5]

Additional gene targets include SUMO1, APOE, and IGF1—all implicated in Alzheimer’s disease pathogenesis. The peptide’s influence on these pathways positions it as a research tool for investigating neurodegenerative processes.

Synaptic plasticity restoration appeared in hippocampal models examining long-term potentiation. Vesugen application in neurodegeneration-simulating conditions showed trends toward restored neuroplasticity, though effects were subtle and model-dependent.^[5]

Epigenetic and Molecular Mechanisms

The mechanistic basis for vesugen’s diverse effects centers on direct interactions with gene regulatory machinery.

Unlike receptor-mediated peptides that activate kinase cascades, vesugen appears to function through physical interactions with DNA and chromatin-associated proteins. This represents a distinct regulatory paradigm in peptide biology.

Direct Gene Regulatory Interactions

Computational modeling suggests vesugen can access the DNA minor groove and contact promoter sequences directly.

The MKI67 promoter binding represents one documented example. Similar interactions may occur at other gene loci, though mapping all potential binding sites requires genome-wide chromatin interaction studies.

Transcription factor modulation provides an alternative mechanism. Some research indicates vesugen may influence the nuclear translocation or DNA-binding activity of factors like FOXO1 and β-catenin.

Studies in mesenchymal stem cells show vesugen inhibits FOXO1 gene expression by 1.6-2.3 fold in specific aging models. The context-dependent nature of this effect—stimulation in some models, inhibition in others—suggests vesugen’s regulatory activity depends on the existing chromatin state.^[6]

Nanomolar concentrations produce these gene regulatory effects. The low concentration requirements align with the epigenetic hypothesis where small amounts of peptide can stabilize or destabilize transcription factor complexes at specific promoters.

Cellular Aging Pathways

Vesugen’s effects on aging-related gene expression extend across multiple pathways involved in cellular senescence.

IGF1 gene expression increased 3.5-5.6 fold in both passage-based and stationary aging models of mesenchymal stem cells. The insulin-like growth factor pathway links metabolic regulation with cell survival and proliferation.^[6]

TNKS2 (tankyrase 2) showed divergent responses depending on the aging model used. Vesugen inhibited TNKS2 expression in passage-aged cells but stimulated it in stationary aging cultures, demonstrating context-dependent regulation.

NF-κB expression increased in response to vesugen across different aging models. This transcription factor coordinates inflammatory responses and cellular stress adaptation.

The peptide’s ability to modulate these interconnected aging pathways makes it a research tool for investigating how short peptides might influence the aging process at the gene expression level. The effects on telomerase-related genes and chromatin structure genes require further investigation to establish direct versus indirect regulatory relationships.

Laboratory Research Applications

Experimental Considerations for Vesugen Research

Laboratory protocols involving vesugen require attention to compound identity, model system selection, and experimental controls.

The peptide’s mechanism through gene regulation means experimental design must account for transcriptional timescales and cell-type specificity. Proper controls and verification methods ensure reproducible results.

Purity and Verification Standards

Gene expression studies demand high-purity peptide reagents to eliminate confounding effects from impurities or degradation products.

Research-grade vesugen should exceed 99% purity as verified by HPLC. The chromatographic profile confirms the peptide exists as a single molecular species without truncation or modification.

LC-MS verification provides molecular weight confirmation and can detect common synthesis errors including incorrect amino acid incorporation. Mass spectrometry also reveals potential oxidation or deamidation that may occur during storage.

Certificate of Analysis (COA) documentation should include sequence confirmation, purity percentage, and endotoxin levels for cell culture applications. These quality control measures prevent experimental artifacts from contaminated or degraded peptide stocks.

Proper storage conditions maintain peptide integrity. Lyophilized vesugen remains stable at -20°C for extended periods, while reconstituted solutions require immediate use or frozen aliquot storage to prevent degradation.

Model System Selection

Primary cells versus immortalized cell lines present different advantages for vesugen research.

Primary vascular endothelial cells or neurons derived from tissue sources may show more physiologically relevant responses but exhibit donor-to-donor variability. Immortalized lines offer reproducibility but may have altered gene expression patterns from transformation.

Passage number becomes critical in aging studies where vesugen’s effects on senescence markers are endpoints. Early-passage cells (P3-P6) versus late-passage cells (P15-P20) provide the aging gradient needed to measure anti-senescence effects.

Tissue-specific versus multipotent stem cell sources influence differentiation studies. Periodontal ligament stem cells demonstrated neuronal marker expression following vesugen exposure, showing these dental-derived cells can serve as neuronal differentiation models.^[3]

In vitro monolayer cultures allow precise concentration control and enable mechanistic studies of gene regulation. Ex vivo tissue preparations preserve three-dimensional architecture but complicate peptide delivery and quantification of effects.

Vesugen in Bioregulator Research Context

Understanding vesugen’s position within the broader bioregulator family helps contextualize its research applications.

The Khavinson bioregulators share common features—short length, tissue-specific origins, and proposed epigenetic mechanisms—yet each compound shows distinct gene regulatory profiles. Comparing vesugen with related bioregulators reveals patterns in tissue-specificity and combinatorial effects.

Pinealon (EDR peptide) represents a neuronal-focused bioregulator with overlapping but distinct effects from vesugen. Both peptides increase GAP43 and nestin expression in neuronal cultures, yet pinealon shows preferential effects on central nervous system markers while vesugen exhibits dual vascular-neuronal activity.

Cardiogen targets cardiac tissue specifically. Research comparing cardiogen and vesugen in vascular models would illuminate whether bioregulator effects derive from tissue origin or sequence-specific regulatory interactions.

Vilon (another dipeptide) shares the ultrashort structure with vesugen but targets immune function. The divergent tissue specificity despite similar size suggests sequence determines regulatory targets rather than length alone.

Publication trends show increasing mechanistic focus on bioregulator research. Early studies documented functional effects in whole organisms, while recent work characterizes gene-level regulation through promoter binding studies and transcriptomic profiling. This progression mirrors the broader peptide research field’s shift toward molecular mechanism elucidation.

Research-Grade Vesugen from BioLongevity Labs

Laboratory investigations into vesugen’s gene regulatory mechanisms require peptide stocks that meet the quality standards necessary for reproducible molecular biology research.

BioLongevity Labs supplies research-grade vesugen under USA GMP protocols with third-party verification. Each batch undergoes independent testing at three separate certified laboratories to confirm identity, purity, and composition.

Comprehensive Certificate of Analysis documentation accompanies every shipment. COAs include HPLC chromatograms, mass spectrometry data, amino acid analysis, and endotoxin testing results—all viewable before purchase at biolongevitylabs.com/all-coas/.

The >99% purity specification ensures gene expression studies and protein interaction assays proceed without confounding signals from peptide impurities. This analytical grade supports the nanomolar concentration ranges used in published vesugen research.

All BioLongevity Labs peptides carry strict research-use-only designations. The compounds are manufactured and documented for laboratory applications in vascular biology, neuronal differentiation studies, aging research, and other scientific protocols requiring verified bioregulatory peptides.

Researchers investigating vascular endothelial regulation, neuronal gene expression, or epigenetic mechanisms in cellular aging can source analytical-grade vesugen with full documentation supporting grant applications and publication requirements.

References

1. Khavinson VKh, Tarnovskaya SI, Linkova NS, Gutop EO, Elashkina EV. Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation in aging. Pleiades Publishing Ltd; 2015. https://doi.org/10.1134/s2079057015040116
2. Lin’kova NS, Drobintseva AO, Orlova OA, Kuznetsova EP, Polyakova VO, Kvetnoy IM, et al. Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro. Springer Science and Business Media LLC; 2016. https://doi.org/10.1007/s10517-016-3370-x
3. Caputi S, Trubiani O, Sinjari B, Trofimova S, Diomede F, Linkova N, et al. Effect of short peptides on neuronal differentiation of stem cells. SAGE Publications; 2019. https://doi.org/10.1177/2058738419828613
4. Kraskovskaya N, Linkova N, Sakhenberg E, Krieger D, Polyakova V, Medvedev D, et al. Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes. MDPI AG; 2024. https://doi.org/10.3390/ijms252111363
5. Khavinson VKh, Lin’kova NS, Umnov RS. Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer’s Disease. Springer Science and Business Media LLC; 2021. https://doi.org/10.1007/s10517-021-05192-6
6. Ashapkin V, Khavinson V, Shilovsky G, Linkova N, Vanuyshin B. Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Springer Science and Business Media LLC; 2020. https://doi.org/10.1007/s11033-020-05506-3

The information presented in this article is for educational and research purposes only, intended for laboratory professionals, researchers and collaborators. This content does not constitute medical or clinical advice.

The Glow Peptide Blend is a three-component research formulation combining GHK-Cu, BPC-157, and TB-500 into a single lyophilized vial.

Each peptide targets a distinct molecular pathway — copper-mediated matrix remodeling, nitric oxide and vascular signaling, and actin-dependent cellular migration. Studied together in preclinical and in vitro systems, the three compounds offer researchers a way to investigate multi-pathway tissue repair, angiogenesis, and inflammatory modulation without parallel administration protocols.

The Three Glow Peptides and Their Mechanisms

The Glow Blend draws research interest because its three components operate through non-overlapping primary mechanisms. Each peptide addresses a different phase or aspect of the tissue repair cascade, which is why the combination is studied as a potential tool for multi-pathway investigation rather than single-target assays.

GHK-Cu (Copper Tripeptide-1)

GHK-Cu is a naturally occurring copper-binding tripeptide (Gly-His-Lys) found in plasma.

In laboratory research, it is studied primarily for its role in extracellular matrix regulation and wound-healing processes. A 2015 review published in BioMed Research Internationalfound that GHK-Cu is capable of modulating at least 4,000 genes, resetting pathological gene expression patterns in preclinical models — a scope that positions it as one of the more broadly studied copper peptides in preclinical research.^[1]

Across laboratory models, GHK-Cu has been shown to stimulate collagen synthesis, promote decorin production, and increase glycosaminoglycan accumulation in skin fibroblasts. It also demonstrates anti-inflammatory activity and draws immune and endothelial cells to injury sites in experimental systems.^[2]

BPC-157 (Body Protection Compound-157)

BPC-157 is a synthetic 15-amino acid pentadecapeptide derived from a protective protein sequence found in gastric juice.

It is studied for its activity across nitric oxide signaling, growth factor receptor modulation, and cytokine regulation in preclinical systems. A 2021 review in Frontiers in Pharmacology documented how BPC-157 upregulates multiple gene expression pathways in rat excision wound models, with parallel activity observed across gastrointestinal, tendon, ligament, muscle, bone, nerve, and vascular tissue models.^[3]

The same review notes BPC-157’s activity across vessel constriction and clot resolution pathways, suggesting a multi-tissue applicability in preclinical wound healing research.

For a full breakdown of BPC-157 preclinical research, see our BPC-157 research guide.

TB-500 (Thymosin Beta-4 Fragment)

TB-500 is a synthetic fragment of Thymosin Beta-4, a highly conserved actin-binding protein involved in cytoskeletal organization and cellular migration.

Its primary mechanism involves actin sequestration and the downstream regulation of cell motility, differentiation, and structural reorganization. A FASEB Journal study characterizing Thymosin Beta-4’s active sites identified a central actin-binding sequence (LKKTETQ) that promotes angiogenesis, wound healing, and cell migration, along with an amino-terminal region associated with inflammation reduction and anti-fibrotic activity.^[4]

A separate review by Goldstein and Kleinman published in Expert Opinion on Biological Therapy summarized the compound’s multifunctional role in stem cell maturation and tissue regeneration and repair, with successful use in multiple clinical trial settings examining dermal wounds, cardiac repair, and neurological models.^[5]

Our TB-500 peptide research article covers the compound’s individual research profile in full.

Why Researchers Study The Glow Peptide Blend

The rationale for combining GHK-Cu, BPC-157, and TB-500 comes down to mechanistic complementarity.

GHK-Cu governs copper-mediated matrix remodeling and oxidative defense at the extracellular level. BPC-157 addresses vascular integrity and cytoprotective signaling through nitric oxide and growth factor receptor pathways. TB-500 handles the cytoskeletal dynamics that govern how cells migrate, differentiate, and reorganize during tissue remodeling.

These are three distinct axes of the repair cascade — not variations on the same mechanism. Combining them in a single formulation lets researchers observe coordinated multi-pathway responses in vitro without designing parallel administration protocols for each compound.

For researchers already working with BPC-157 and TB-500 in combination, the addition of GHK-Cu extends the model into extracellular matrix dynamics and copper-dependent antioxidant activity — areas the two-peptide stack does not address.

Glow Blend Composition at BioLongevity Labs

BioLongevity Labs’ Glow Peptide Blend is supplied as a 70 mg lyophilized vial with the following composition:

All three peptides are supplied in a freeze-dried, filler-free state. Reconstitute with sterile solvent immediately prior to experimental use and store aliquots at ≤ –20°C to avoid repeated freeze-thaw cycles. See our lyophilized for full storage protocol.

Researchers investigating inflammatory pathway modulation alongside matrix remodeling may also consider our KLOW Blend — an 80 mg formulation that adds KPV (a tripeptide derived from alpha-MSH) to the Glow Blend base for studies examining immune-modulatory pathways alongside tissue signaling.

In Vitro Research Applications

Research-Grade Standards for Glow Blend Studies

Reproducible preclinical data depends on compound purity and verified composition. Impurities, incorrect ratios, or undisclosed excipients introduce confounding variables that compromise experimental validity.

BioLongevity Labs’ Glow Blend is independently verified by three separate certified laboratories using HPLC (for purity confirmation) and LC-MS (for molecular identity). Each batch ships with a full Certificate of Analysis available before purchase at biolongevitylabs.com/all-coas.

All three components are confirmed at greater than 99% purity. The formulation contains no fillers or additives — only the active peptide compounds, lyophilized under GMP-aligned manufacturing conditions at a USA-registered facility.

For guidance on evaluating supplier documentation, our how to read a peptide COA and third-party tested peptides articles outline what labs should look for before sourcing any research compound.

References

1. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Wiley; 2015. https://doi.org/10.1155/2015/648108
2. Pickart L. The human tri-peptide GHK and tissue remodeling. Informa UK Limited; 2008. https://doi.org/10.1163/156856208784909435
3. Seiwerth S, Milavic M, Vukojevic J, Gojkovic S, Krezic I, Vuletic LB, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers Media SA; 2021. https://doi.org/10.3389/fphar.2021.627533
4. 4. Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin ß4 defined by active sites in short peptide sequences. Wiley; 2010. https://doi.org/10.1096/fj.09-142307
5. Goldstein AL, Kleinman HK. Advances in the basic and clinical applications of thymosin β                     4. Informa UK Limited; 2015. https://doi.org/10.1517/14712598.2015.1011617